Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 22 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Strybol Wout Pharma from Brugge, company number BE0712514587, closed financial year 2025 with a result of € 155,593 after tax. For that financial year Strybol Wout Pharma recorded a gross margin of € 232,433 and equity of € 56,774. Compared with financial year 2024, the result moved from € 32,804 to € 155,593. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.
€ 56,774
▲ 10% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 155,593
▲ € 122,789 vs 2024
Profit after tax over the fiscal year.
€ 12,243
▼ 79% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 150,223 paid out
97 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
€ 3,534
▼ 23% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 1.8 million
€ 183,095 is repaid this year. At this pace the long-term loan is gone in ≈ 10 years.
€ 3,509
▲ € 3,064 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 16,486
▲ 156% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 44,743 | € 38,143 | € 45,350 | € 232,433 | ▲ € 187,083 |
| Profit after taxes | € 33,686 | € 26,452 | € 32,804 | € 155,593 | ▲ € 122,789 |
| Equity | € 148,504 | € 162,356 | € 51,404 | € 56,774 | ▲ 10% |
| Total debts | € 11,300 | € 8,254 | € 107,137 | € 2,111,243 | ▲ € 2 million |
| Cash | € 96,449 | € 54,585 | € 59,027 | € 12,243 | ▼ 79% |
| Retained profit | € 142,304 | € 143,756 | € 32,804 | € 38,174 | ▲ 16% |
| Dividend | € 0 | € 25,000 | € 143,756 | € 150,223 | ▲ 4% |
| Bank debt | € 0 | € 0 | € 0 | € 1,845,117 | |
| Balance sheet total | € 159,804 | € 170,611 | € 158,541 | € 2,168,017 | ▲ € 2 million |
Key figures of Strybol Wout Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Strybol Wout Pharma?
What happened at Strybol Wout Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 155,593 (▲ € 122,789 vs 2024). Source: NBB ↗
- New establishment in Maldegem. KBO
- Start of the company according to the CBE. KBO
- Wout Strybol became a director. NBB
In short
From € 33,686 profit in 2022 to € 155,593 profit in 2025.
Paid € 85,560 in corporate taxes since 2022.
Best year ever: 2025, with € 155,593 profit.
Paid out € 318,980 in dividends to the owners in total.
A new publication or filing at Strybol Wout Pharma? We notify you, reason included.
Follow Strybol Wout PharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Strybol Wout Pharma is Wout Strybol. It owns 50% of Strybol Sint Trudo (Ap Jan Carton), 50% of Strybol De Zeven Torentjes (Ap Debaenst), 45% of Strybol De Berken, 45% of Strybol Sint Gillis, 45% of Strybol Pharma Groep and 45% of Strybol De Rotonde itself.
Directors
According to the 2025 annual accounts
Wout Strybol
Director
since 2018
Establishments
Establishment units
Physical locations of this company
Zilversparrenstraat 29
8310 Brugge
Donkstraat 120 box A
9990 Maldegem
Active since 24 October 2018
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0712.514.587
- VAT number
- BE 0712.514.587
- Registered office
- Zilversparrenstraat 29, 8310 Brugge
- Names & denominations
- Strybol Wout Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 24 October 2018
- Peppol
- Active · Active since 30 Jan 2025
- Activities · NACE
Overige zakelijke dienstverlening, neg